US4492760A
Expired / Lapsed
US
⏱️ 0.0 years remaining
HLA D Typing assay
Assignee: The Wistar Institute
•
Filing: 1983-04-19
•
Granted: 1985-01-08
•
Expires: 2003-04-19
Abstract
Abstract An assay for HLA D phenotype wherein antigen-pulsed monocytes are contacted with antigen-specific T lymphocytes or T cell hybridomas and the extent of selective binding between the pulsed monocytes and the T lymphocytes or T cell hybridomas determines HLA D phenotype of the monocyte. The assay is particularly useful for quickly typing donor tissue prior to transplantation.
Inventors
- 👤 Elaine C. DeFreitas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 23:12
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56966; G01N33/56977; G01N33/56972; A; A61; A61K; A61K39/00; A61K2039/51; A61K2039/515; A61K2039/5158; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S436/00; Y10S436/804; Y10S436/811; Y10S436/815; Y10S436/823
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
82 words
A method of determining the HLA D type of human monocytes comprising: (a) pulsing human monocytes with a particular antigen; (b) contacting said pulsed monocyte with at least one screening cell culture selected from the group consisting of antigen-specific T lymphocytes and antigen-specific T cell hybridomas, the cells in each said screening cell culture being substantially of a single HLA D binding type and specific for said particular antigen; and (c) determining whether said pulsed monocytes selectively bind to said screening cells.
Claim 2
Independent Claim
82 words
A method of determining the HLA D type of human monocytes comprising: (a) pulsing human monocytes with a particular antigen; (b) contacting said pulsed monocyte with at least one screening cell culture selected from the group consisting of antigen-specific T lymphocytes and antigen-specific T cell hybridomas, the cells in each said screening cell culture being substantially of a single HLA D binding type and specific for said particular antigen; and (c) determining whether said pulsed monocytes selectively bind to said screening cells.
Claim 3
Dependent Claim
50 words
The method of claim 1 wherein said pulsed monocytes are contacted with more than one screening culture of different HLA D binding types, the quantity of said pulsed monocytes contacted to each screening culture being approximately equal and each of said screening cultures having an approximately equal number of cells.
Claim 4
Dependent Claim
15 words
The method of claim 1 wherein said pulsed monocytes are attached to a solid support.
Claim 5
Dependent Claim
15 words
The method of claim 2 wherein said pulsed monocytes are attached to a solid support.
Claim 6
Dependent Claim
11 words
The method of claim 1 wherein said screening cultures are radiolabeled.
Claim 7
Dependent Claim
11 words
The method of claim 2 wherein said screening cultures are radiolabeled.
Claim 8
Dependent Claim
11 words
The method of claim 3 wherein said screening cultures are radiolabeled.
Claim 9
Dependent Claim
11 words
The method of claim 4 wherein said screening cultures are radiolabeled.
Claim 10
Dependent Claim
12 words
The method of claim 1 wherein said screening cultures are enzyme labeled.
Claim 11
Dependent Claim
12 words
The method of claim 2 wherein said screening cultures are enzyme labeled.
Claim 12
Dependent Claim
12 words
The method of claim 3 wherein said screening cultures are enzyme labeled.
Claim 13
Dependent Claim
12 words
The method of claim 4 wherein said screening cultures are enzyme labeled.
Claim 14
Dependent Claim
51 words
The method of claim 1 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal, human T lymphocyte specific for said particular antigen.
Claim 15
Dependent Claim
51 words
The method of claim 2 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 16
Dependent Claim
51 words
The method of claim 3 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 17
Dependent Claim
51 words
The method of claim 4 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 18
Dependent Claim
51 words
The method of claim 5 wherein said screening cultures are cultures of human T cell hybridomas cloned with a somatic cell hybrid of a first parent cell derived from a human lymphoma cell, line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 19
Dependent Claim
51 words
The method of claim 6 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 20
Dependent Claim
51 words
The method of claim 7 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 21
Dependent Claim
51 words
The method of claim 8 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 22
Dependent Claim
51 words
The method of claim 9 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 23
Dependent Claim
51 words
The method of claim 10 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 24
Dependent Claim
51 words
The method of claim 11 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 25
Dependent Claim
51 words
The method of claim 12 wherein said screening cultures are cultures of human T cell hybridomas cloned from a somatic cell hybrid of a first parent cell derived from a human lymphoma cell line and a second parent cell that is a normal human T lymphocyte specific for said particular antigen.
Claim 26
Dependent Claim
19 words
The method of claim 13 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 27
Dependent Claim
19 words
The method of claim 14 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 28
Dependent Claim
19 words
The method of claim 15 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 29
Dependent Claim
19 words
The method of claim 16 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 30
Dependent Claim
19 words
The method of claim 17 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 31
Dependent Claim
19 words
The method of claim 18 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 32
Dependent Claim
19 words
The method of claim 19 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 33
Dependent Claim
19 words
The method of claim 20 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 34
Dependent Claim
19 words
The method of claim 21 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 35
Dependent Claim
19 words
The method of claim 22 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 36
Dependent Claim
19 words
The method of claim 23 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
Claim 37
Dependent Claim
19 words
The method of claim 24 wherein said first parent cell is derived from the human lymphoma cell line Jurkat.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-01-08 | 1988-07-09 | 1989-01-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-01-08 | 1992-07-09 | 1993-01-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-01-08 | 1996-07-09 | 1997-01-08 | $7700.00 | Window Closed / Lapsed |